André van Maurik

1.3k total citations
35 papers, 927 citations indexed

About

André van Maurik is a scholar working on Immunology, Rheumatology and Physiology. According to data from OpenAlex, André van Maurik has authored 35 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology, 7 papers in Rheumatology and 6 papers in Physiology. Recurrent topics in André van Maurik's work include T-cell and B-cell Immunology (16 papers), Immune Cell Function and Interaction (12 papers) and Immunotherapy and Immune Responses (10 papers). André van Maurik is often cited by papers focused on T-cell and B-cell Immunology (16 papers), Immune Cell Function and Interaction (12 papers) and Immunotherapy and Immune Responses (10 papers). André van Maurik collaborates with scholars based in United Kingdom, United States and Netherlands. André van Maurik's co-authors include Kathryn J. Wood, Nick D. Jones, Peter J. Morris, Masaki Hara, Bernd M. Spriewald, Oliver Witzke, Stuart E. Turvey, Clare Smith, Andrew L. Mellor and Cherry Kingsley and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and Annals of Surgery.

In The Last Decade

André van Maurik

34 papers receiving 917 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
André van Maurik United Kingdom 16 588 197 128 128 105 35 927
Richard Batchelor United Kingdom 13 694 1.2× 140 0.7× 74 0.6× 65 0.5× 161 1.5× 21 1.2k
Masaaki Toda Japan 3 1.1k 2.0× 98 0.5× 46 0.4× 104 0.8× 47 0.4× 5 1.4k
Michel Y. Braun Belgium 21 780 1.3× 150 0.8× 35 0.3× 52 0.4× 115 1.1× 37 1.1k
Bita Ansaripour Iran 16 332 0.6× 91 0.5× 115 0.9× 57 0.4× 59 0.6× 39 717
KI Welsh United Kingdom 16 465 0.8× 86 0.4× 119 0.9× 191 1.5× 26 0.2× 29 895
Guido Wolff-Vorbeck Germany 15 836 1.4× 92 0.5× 80 0.6× 260 2.0× 31 0.3× 40 1.3k
M. J. Giphart Netherlands 14 543 0.9× 148 0.8× 131 1.0× 279 2.2× 21 0.2× 27 937
Rebecca A. Shilling United States 17 362 0.6× 268 1.4× 33 0.3× 33 0.3× 98 0.9× 33 799
M. J. Giphart Netherlands 18 616 1.0× 127 0.6× 114 0.9× 254 2.0× 30 0.3× 45 937
Heiko Hawlisch Germany 13 696 1.2× 75 0.4× 53 0.4× 29 0.2× 72 0.7× 16 1.0k

Countries citing papers authored by André van Maurik

Since Specialization
Citations

This map shows the geographic impact of André van Maurik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André van Maurik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André van Maurik more than expected).

Fields of papers citing papers by André van Maurik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by André van Maurik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André van Maurik. The network helps show where André van Maurik may publish in the future.

Co-authorship network of co-authors of André van Maurik

This figure shows the co-authorship network connecting the top 25 collaborators of André van Maurik. A scholar is included among the top collaborators of André van Maurik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with André van Maurik. André van Maurik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Denton, Christopher P., Robert Spiera, David J. Jörg, et al.. (2023). AB0904 BELIMUMAB FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS: A PHASE 2/3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Annals of the Rheumatic Diseases. 82. 1668–1668. 1 indexed citations
2.
Gillespie, William R., et al.. (2023). Population model‐based analysis of the memory B‐cell response following belimumab therapy in the treatment of systemic lupus erythematosus. CPT Pharmacometrics & Systems Pharmacology. 12(4). 462–473. 4 indexed citations
3.
McClure, Mark, Seerapani Gopaluni, James Wason, et al.. (2023). A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol. Trials. 24(1). 180–180. 11 indexed citations
4.
5.
Mariette, Xavier, Francesca Barone, Chiara Baldini, et al.. (2022). A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome. JCI Insight. 7(23). 70 indexed citations
6.
Keymeulen, Bart, André van Maurik, David R. Inman, et al.. (2020). A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes. Diabetologia. 64(2). 313–324. 38 indexed citations
7.
8.
Vossenkämper, Anna, Christian Hundsrucker, Kevin Page, et al.. (2014). A CD3-Specific Antibody Reduces Cytokine Production and Alters Phosphoprotein Profiles in Intestinal Tissues From Patients With Inflammatory Bowel Disease. Gastroenterology. 147(1). 172–183. 28 indexed citations
9.
Sabarth, Nicolas, M. Keith Howard, Helga Savidis-Dacho, et al.. (2009). Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine. 28(3). 650–656. 23 indexed citations
10.
Maurik, André van, Nicolas Sabarth, P Brühl, et al.. (2009). Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination. Vaccine. 28(7). 1778–1785. 16 indexed citations
11.
Maurik, André van, Barbara Fazekas de St Groth, Kathryn J. Wood, & Nick D. Jones. (2004). Dependency of Direct Pathway CD4+ T Cells on CD40-CD154 Costimulation Is Determined by Nature and Microenvironment of Primary Contact with Alloantigen. The Journal of Immunology. 172(4). 2163–2170. 15 indexed citations
12.
13.
Maurik, André van, Kathryn J. Wood, & Nick D. Jones. (2002). Impact of both donor and recipient strains on cardiac allograft survival after blockade of the CD40-CD154 costimulatory pathway1. Transplantation. 74(5). 740–743. 15 indexed citations
14.
Jones, Nick D., Stuart E. Turvey, André van Maurik, et al.. (2001). Differential Susceptibility of Heart, Skin, and Islet Allografts to T Cell-Mediated Rejection. The Journal of Immunology. 166(4). 2824–2830. 136 indexed citations
15.
Jones, Nick D., André van Maurik, Bernd M. Spriewald, et al.. (2000). CD40-CD40L independent activation of CD8+T cells can trigger allograft rejection.. Transplantation. 69. 3 indexed citations
16.
Ensminger, Stephan, Bernd M. Spriewald, Oliver Witzke, et al.. (2000). INTRAGRAFT INTERLEUKIN-4 mRNA EXPRESSION AFTER SHORT-TERM CD154 BLOCKADE MAY TRIGGER DELAYED DEVELOPMENT OF TRANSPLANT ARTERIOSCLEROSIS IN THE ABSENCE OF CD8+ T CELLS1. Transplantation. 70(6). 955–963. 26 indexed citations
17.
Hara, Masaki, Nick D. Jones, André van Maurik, et al.. (1999). In vivo differentiation of alloreactive CD8+ T cells after murine cardiac allograft transplantation. Transplantation Proceedings. 31(1-2). 130–130. 1 indexed citations
18.
Hara, Masaki, Nick D. Jones, André van Maurik, et al.. (1999). In vivo cytokine production by allospecific CD8+ transgenic T cells after heart transplantation. Transplantation Proceedings. 31(1-2). 91–91. 1 indexed citations
19.
Barbara, J. A. J., Masaki Hara, André van Maurik, et al.. (1999). THE VISUALIZATION OF T CELL RESPONSES1. Transplantation. 67(12). 1508–1514. 1 indexed citations
20.
Jones, Nick D., et al.. (1999). T-Cell Activation, Proliferation, and Memory After Cardiac Transplantation In Vivo. Annals of Surgery. 229(4). 570–578. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Batchelor Breakdown of academic impact, for papers by Masaaki Toda Breakdown of academic impact, for papers by Michel Y. Braun Breakdown of academic impact, for papers by Bita Ansaripour Breakdown of academic impact, for papers by KI Welsh Breakdown of academic impact, for papers by Guido Wolff-Vorbeck Breakdown of academic impact, for papers by M. J. Giphart Breakdown of academic impact, for papers by Rebecca A. Shilling Breakdown of academic impact, for papers by M. J. Giphart Breakdown of academic impact, for papers by Heiko Hawlisch
Rankless by CCL
2026